File(s) not publicly available
Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life
journal contributionposted on 2018-11-01, 00:00 authored by Donald D Chang, Harris A Eyreeuro, Ryan Abbott, Michael Coudreaut, Bernhard T Baune, Jeffrey A Shaman, Helen Lavretsky, Eric J Lenze, David A Merrill, Ajeet SinghAjeet Singh, Benoit H Mulsant, Charles F Reynolds, Daniel J Müller, Chad Bousman
Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.
Pagination1269 - 1284
Publication classificationC1 Refereed article in a scholarly journal
CategoriesNo categories selected
decision support toolslate-life depressionmajor depressionpharmacogenomicsprecision medicineScience & TechnologyLife Sciences & BiomedicinePharmacology & PharmacyGENE PROMOTER POLYMORPHISMSEROTONIN TRANSPORTERTREATMENT RESPONSEIMPLEMENTATION CONSORTIUMANTIDEPRESSANT-TREATMENTOLDER-ADULTSDOUBLE-BLINDGERIATRIC DEPRESSIONCYP2C19 GENOTYPES